Equivalent outcomes with primary and retransplantation in African-American deceased-donor renal allograft recipients

详细信息    查看全文

• 作者：Scott A. Gruber ; Kristian L. Brown ; Jose M. El-Amm ; Atul Singh ; Kalyani Mehta ; Katherina Morawski ; Elizabeth Cincotta ; S ; ra Nehlsen-Cannarella ; Julian E. Losanoff ; Miguel S. West ; Mona D. Doshi
• 刊名：Surgery
• 出版年：2009
• 出版时间：October 2009
• 年：2009
• 卷：146
• 期：4
• 页码：646-653
• 全文大小：219 K

文摘

Background

Graft survival following renal retransplantation has been inferior to that following primary allografting, particularly in African Americans (AAs) receiving deceased-donor (DD) kidneys.

Methods

Among 166 AA DD renal allograft recipients transplanted from July 2001 through July 2007, we compared the outcomes of 26 (16 % ) receiving a second graft with those of 140 primary cases. All patients received either thymoglobulin (ATG) or an IL-2 receptor antagonist for induction, and were maintained on either tacrolimus or sirolimus + mycophenolate mofetil ± prednisone.

Results

When compared with primary transplants, regrafts received kidneys from older donors, were younger, more sensitized, more likely to receive ATG and to be maintained on prednisone, received more doses of ATG, and were less likely diabetic. There was no difference between primary and retransplant groups in overall patient or graft survival; incidence of acute rejection, CMV infection, BK nephropathy, or new-onset diabetes mellitus; and serum creatinine at 1 year.

Conclusion

AA renal allograft recipients can undergo a second DD transplant with intermediate-term outcomes comparable to that of a primary graft, despite the presence of multiple immunologic and non-immunologic high-risk factors, by extending the course of ATG induction and continuing prednisone therapy in the vast majority of cases.